Beta Bionics, Inc. (NASDAQ:BBNX) Stock Short Interest Report for September

Beta Bionics, Inc. (NASDAQ:BBNX) was the target of a large decrease in short interest in September. As of September 30th, there was short interest totaling 6,046,389 shares, a decrease of 43.1% from the September 15th total of 10,617,768 shares. Based on an average daily volume of 1,859,712 shares, the short-interest ratio is presently 3.3 days. Currently, 14.2% of the shares of the company are sold short.

Insider Activity

In other news, insider Mark Hopman sold 30,779 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total transaction of $619,581.27. Following the sale, the insider directly owned 56,479 shares in the company, valued at $1,136,922.27. This trade represents a 35.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,675 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the sale, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. The trade was a 4.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 97,697 shares of company stock valued at $1,907,034 in the last three months. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Beta Bionics during the 2nd quarter valued at about $62,000. The Manufacturers Life Insurance Company bought a new position in shares of Beta Bionics during the 2nd quarter valued at $172,000. Ieq Capital LLC acquired a new stake in shares of Beta Bionics in the second quarter worth about $229,000. Finally, Quantbot Technologies LP bought a new stake in Beta Bionics during the second quarter worth approximately $264,000.

Beta Bionics Trading Up 0.6%

Shares of BBNX traded up $0.10 during midday trading on Friday, reaching $17.41. 48,597 shares of the company were exchanged, compared to its average volume of 1,173,122. The company has a market cap of $783.28 million, a price-to-earnings ratio of -10.56 and a beta of 3.39. Beta Bionics has a 1-year low of $8.80 and a 1-year high of $32.71. The stock has a 50-day moving average price of $19.04 and a 200-day moving average price of $15.19.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Equities research analysts anticipate that Beta Bionics will post -2.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. UBS Group reiterated a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a report on Tuesday, September 15th. The Goldman Sachs Group raised their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. William Blair assumed coverage on shares of Beta Bionics in a research note on Friday, August 21st. They set a “market perform” rating for the company. Wells Fargo & Company initiated coverage on shares of Beta Bionics in a research note on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 target price for the company. Finally, Robert W. Baird raised their target price on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Several firms, including Berger Montague, Kaplan Fox and Faruqi & Faruqi, reminded investors that November 3, 2026 is the deadline to seek lead-plaintiff status in the federal securities class action covering purchases from July 30, 2025, through February 24, 2026. Berger Montague securities fraud notice
• Negative Sentiment: The lawsuit alleges that Beta Bionics and certain executives misled investors about the iLet system’s viability, efficacy and regulatory compliance. Allegations cited in the notices include a June 2025 FDA Form 483, more than 18,000 unreported customer complaints and the abandonment of a built-in safety feature in the dosing algorithm. The claims have not been proven. Levi and Korsinsky Beta Bionics investor alert
• Negative Sentiment: The legal campaign follows disclosures that allegedly contributed to a roughly 72% decline in BBNX during the class period. Additional lawsuits or regulatory scrutiny could increase litigation costs, reputational risk and uncertainty around the iLet product. Hagens Berman Beta Bionics class action

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.